-
Website
http://www.thinkgene.com -
Original page
http://www.thinkgene.com/absence-of-high-penatrance-in-snp-genomic-services/ -
Subscribe
All Comments -
Community
-
Top Commenters
-
Andrew Yates
68 comments · 1 points
-
pnorth00
3 comments · 1 points
-
Wholesale Clothing
11 comments · 1 points
-
Jay Parkinson, MD
3 comments · 7 points
-
Sciphu
6 comments · 2 points
-
-
Popular Threads
“In the case of the BRCA genes, only a relatively small proportion of the population – as low as 5% - carry one or more of these genes. We are focused on SNPs that are apparent within whole populations. We make it clear in our literature that we do not test for this type of gene.”
Yeah, and it just so happens that the 10% (not 5%) actually has medically actionable validity....
-Steve
-Steve
www.thegenesherpa.blogspot.com
“The reality is that except for a few enthusiasts (like anyone in the DNA Network, including myself), existing SNP genomic services just aren’t that useful. It’s not useful to know that one has a 7% lifetime risk rather than a 5%. I need to know risks of about 40% and higher.”
In response to Mr. Andrew Yates I offer the following information about lifetime risk assessments offered by Navigenics (www.navigenics.com).
On the Navigenics HealthCompass six conditions have a lifetime risk potential that exceeds 35% (Five conditions exceed 40%). Since some conditions are less common in the population, it is useful to also consider relative risk, as opposed to absolute risk.
Half of all 23 conditions reported have a relative risk (compared to the average genetic risk in the general population) greater than 2; seven conditions, greater than 3; and three conditions greater than 4. For comparison, this level of relative risk is in line with other well-accepted, commonly used risk factors such as positive family history and environmental risk factors (high lipids, age at menopause etc.)
I hope this clarifies things for Mr. Yates who can now feel better about being an enthusiast.
I would also ask Mr. Yates to reconsider his statement about why Navigenics is not doing BRCA testing. Patent considerations aside, it is of import only in about 5% of breast cancer cases (those with “extreme” positive family histories and early age of onset). The contribution of BRCA1/2 mutations in sporadic breast cancers has not been determined conclusively. Our preference is truly to offer a test that is applicable to the majority of individuals. We are cognizant that in a minority of people BRCA testing is important and have addressed this issue on our web site in several places. We realize that no test is complete in and of itself; otherwise people would have heart surgery based only on a treadmill. So, I would ask Mr. Yates to please give us credit for more than trying to get around patent considerations. We are enthusiasts as well.